Literature DB >> 25482939

HDAC6 regulates neuroblastoma cell migration and may play a role in the invasion process.

Linlin Zhang1, Ningning Liu, Songbo Xie, Xianfei He, Jun Zhou, Min Liu, Dengwen Li.   

Abstract

Neuroblastoma is one of the most prevalent pediatric extracranial solid tumors and is often diagnosed after dissemination has occurred. Despite recent advances in multimodal therapies of this malignancy, its therapeutic efficacy remains poor. Novel treatment strategies are thus in great need. Herein, we demonstrate that histone deacetylase 6 (HDAC6), a member of the deacetylase family that is localized predominantly in the cytoplasm, is involved in neuroblastoma dissemination. HDAC6 expression in neuroblastoma tissue samples varied with the site of the tumor. HDAC6 showed little impact on the proliferation of neuroblastoma cells. Instead, downregulation of HDAC6 expression by RNA interference or inhibition of its catalytic activity by the pharmacological inhibitor tubacin significantly decreased the migration of 3 human malignant neuroblastoma cell lines and reduced the invasion ability of one of the 3 cell lines, but only slightly affected the migration and invasion of human normal brain glial cells. Our data further revealed that the regulation of neuroblastoma cell migration by HDAC6 was mediated by its effects on cell polarization and adhesion. These findings suggest a role for HDAC6 in neuroblastoma dissemination and a potential of using HDAC6 inhibitors for the treatment of this malignancy.

Entities:  

Keywords:  DAPI, 4′, 6-diamidino-2-phenylindole; HDAC6; HDAC6, histone deacetylase 6; MTT, 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide; SRB, sulforhodamine B; adhesion; calcein-AM, calcein-acetoxymethyl; cell invasion; cell migration; dissemination; neuroblastoma; polarization

Mesh:

Substances:

Year:  2014        PMID: 25482939      PMCID: PMC5113315          DOI: 10.4161/15384047.2014.956632

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  40 in total

1.  Histone deacetylase inhibitor BL1521 induces a G1-phase arrest in neuroblastoma cells through altered expression of cell cycle proteins.

Authors:  Krista Ouwehand; Annemieke J M de Ruijter; Chris van Bree; Huib N Caron; André B P van Kuilenburg
Journal:  FEBS Lett       Date:  2005-02-28       Impact factor: 4.124

Review 2.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.

Authors:  Saverio Minucci; Pier Giuseppe Pelicci
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

3.  Active maintenance of mHDA2/mHDAC6 histone-deacetylase in the cytoplasm.

Authors:  A Verdel; S Curtet; M P Brocard; S Rousseaux; C Lemercier; M Yoshida; S Khochbin
Journal:  Curr Biol       Date:  2000-06-15       Impact factor: 10.834

4.  Late relapse and prognosis for neuroblastoma patients surviving 5 years or more: a report from the European Neuroblastoma Study Group "Survey".

Authors:  S J Cotterill; A D Pearson; J Pritchard; J A Kohler; A B Foot
Journal:  Med Pediatr Oncol       Date:  2001-01

Review 5.  Recent advances in neuroblastoma.

Authors:  John M Maris
Journal:  N Engl J Med       Date:  2010-06-10       Impact factor: 91.245

Review 6.  Mechanisms of invasion and metastasis in human neuroblastoma.

Authors:  Tasnim Ara; Yves A DeClerck
Journal:  Cancer Metastasis Rev       Date:  2006-12       Impact factor: 9.264

Review 7.  Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

Authors:  G M Brodeur; J Pritchard; F Berthold; N L Carlsen; V Castel; R P Castelberry; B De Bernardi; A E Evans; M Favrot; F Hedborg
Journal:  J Clin Oncol       Date:  1993-08       Impact factor: 44.544

8.  Histone deacetylase 6 and cytoplasmic linker protein 170 function together to regulate the motility of pancreatic cancer cells.

Authors:  Dengwen Li; Xiaodong Sun; Linlin Zhang; Bing Yan; Songbo Xie; Ruming Liu; Min Liu; Jun Zhou
Journal:  Protein Cell       Date:  2013-11-21       Impact factor: 14.870

Review 9.  Targeting tumor cell motility as a strategy against invasion and metastasis.

Authors:  Alan Wells; Jelena Grahovac; Sarah Wheeler; Bo Ma; Douglas Lauffenburger
Journal:  Trends Pharmacol Sci       Date:  2013-04-06       Impact factor: 14.819

10.  RuvBL2 is involved in histone deacetylase inhibitor PCI-24781-induced cell death in SK-N-DZ neuroblastoma cells.

Authors:  Qinglei Zhan; Sauna Tsai; Yonghai Lu; Chunmei Wang; Yiuwa Kwan; Saiming Ngai
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

View more
  11 in total

Review 1.  HDAC6: A unique HDAC family member as a cancer target.

Authors:  Sumeet Kaur; Prerna Rajoria; Madhu Chopra
Journal:  Cell Oncol (Dordr)       Date:  2022-08-29       Impact factor: 7.051

2.  Synthesis, Biochemical, and Cellular Evaluation of HDAC6 Targeting Proteolysis Targeting Chimeras.

Authors:  Salma Darwish; Tino Heimburg; Johannes Ridinger; Daniel Herp; Matthias Schmidt; Christophe Romier; Manfred Jung; Ina Oehme; Wolfgang Sippl
Journal:  Methods Mol Biol       Date:  2023

3.  Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.

Authors:  Geoffrey M Matthews; Parinaz Mehdipour; Leonie A Cluse; Katrina J Falkenberg; Eric Wang; Mareike Roth; Fabio Santoro; Eva Vidacs; Kym Stanley; Colin M House; James R Rusche; Christopher R Vakoc; Johannes Zuber; Saverio Minucci; Ricky W Johnstone
Journal:  Blood       Date:  2015-10-07       Impact factor: 22.113

4.  HDAC6 regulates antibody-dependent intracellular neutralization of viruses via deacetylation of TRIM21.

Authors:  Songbo Xie; Linlin Zhang; Dan Dong; Ruixin Ge; Qianqian He; Cunxian Fan; Wei Xie; Jun Zhou; Dengwen Li; Min Liu
Journal:  J Biol Chem       Date:  2020-08-12       Impact factor: 5.157

5.  TDP-43/HDAC6 axis promoted tumor progression and regulated nutrient deprivation-induced autophagy in glioblastoma.

Authors:  Tzu-Wei Lin; Ming-Teh Chen; Liang-Ting Lin; Pin-I Huang; Wen-Liang Lo; Yi-Ping Yang; Kai-Hsi Lu; Yi-Wei Chen; Shih-Hwa Chiou; Cheng-Wen Wu
Journal:  Oncotarget       Date:  2017-05-18

6.  Inhibition of HDAC6 activity through interaction with RanBPM and its associated CTLH complex.

Authors:  Louisa M Salemi; Matthew E R Maitland; Eyal R Yefet; Caroline Schild-Poulter
Journal:  BMC Cancer       Date:  2017-07-01       Impact factor: 4.430

7.  A New Histone Deacetylase Inhibitor, MHY219, Inhibits the Migration of Human Prostate Cancer Cells via HDAC1.

Authors:  Umasankar De; Soma Kundu; Nabanita Patra; Mee Young Ahn; Ji Hae Ahn; Ji Yeon Son; Jung Hyun Yoon; Hyung Ryoung Moon; Byung Mu Lee; Hyung Sik Kim
Journal:  Biomol Ther (Seoul)       Date:  2015-09-01       Impact factor: 4.634

Review 8.  Cell Proliferation in Neuroblastoma.

Authors:  Laura L Stafman; Elizabeth A Beierle
Journal:  Cancers (Basel)       Date:  2016-01-12       Impact factor: 6.639

9.  Molecular mechanisms of OLIG2 transcription factor in brain cancer.

Authors:  Igor F Tsigelny; Valentina L Kouznetsova; Nathan Lian; Santosh Kesari
Journal:  Oncotarget       Date:  2016-08-16

10.  Histone deacetylase 6 modulates macrophage infiltration during inflammation.

Authors:  Bing Yan; Songbo Xie; Yang Liu; Wenxuan Liu; Dengwen Li; Min Liu; Hongbo R Luo; Jun Zhou
Journal:  Theranostics       Date:  2018-04-18       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.